E-Mail
IMAGE: Researchers at The University of Tokyo use the mathematics of adaptive learning and artificial intelligence to describe how T helper cells adjust the response of the vertebrate immune system, which. view more
Credit: Institute of Industrial Science, the University of Tokyo
Tokyo, Japan - Scientists from the Institute of Industrial Science at The University of Tokyo demonstrated how the adaptive immune system uses a method similar to reinforcement learning to control the immune reaction to repeat infections. This work may lead to significant improvements in vaccine development and interventions to boost the immune system.
In the human body, the adaptive immune system fights germs by remembering previous infections so it can respond quickly if the same pathogens return. This complex process depends on the cooperation of many cell types. Among these are T helpers, which assist by coordinating the response of other parts of the immune system called effector
Learning to Help the Adaptive Immune System asiaresearchnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from asiaresearchnews.com Daily Mail and Mail on Sunday newspapers.
World Health Organisation ‘misleading the world’ on Covid and alcohol, claims professor of nutrition 5th March, 2021 by Patrick Schmitt
During an online seminar last week, German doctor and professor Nicolai Worm claimed that the World Health Organisation was “misleading the world” when it comes to Covid-19 and alcohol.
The event was designed to look at the scientific evidence surrounding various claims circulating in the media during the current pandemic, most notably concerning the relationship between people’s immune response to Covid-19 and their consumption of alcohol.
Called
Wine and COVID-19: fake news or facts, it was held on 2 March and led by Nicolai, who is a nutrition consultant, lecturer and professor of nutrition at the German University of Prevention and Health Care Management.
T-Detect is currently under review by the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) Patients can conveniently opt to visit one of nearly 2,000 Labcorp sites or arrange for a mobile phlebotomy service at their home SEATTLE, Feb. 23, 2021 (GLOBE NEWSWIRE) Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the launch of T-Detect™ COVID, the first clinical T-cell based test to confirm recent or prior COVID-19 infection. In real-world studies, this first-in-class test outperformed leading antibody tests. Knowledge of prior COVID-19 infection is critically important for those who believe they may have been infected with the virus but have not been able to confirm a diagnosis. T-Detect is currently under review by the U.S. Food and Drug Administration (FDA) for Emergency U